Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enzo Biochem (ENZ)

Enzo Biochem (ENZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enzo Biochem 21 Executive Blvd. FARMINGDALE NY 11735 USA

www.enzo.com Employees: 136 P: 631-755-5500

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.

Key Statistics

Overview:

Market Capitalization, $K 16,444
Enterprise Value, $K -35,736
Shares Outstanding, K 52,403
Annual Sales, $ 31,910 K
Annual Net Income, $ -26,080 K
Last Quarter Sales, $ 7,330 K
Last Quarter Net Income, $ -1,540 K
EBIT, $ -9,920 K
EBITDA, $ -8,650 K
60-Month Beta 1.19
% of Insider Shareholders 11.40%
% of Institutional Shareholders 36.90%
Float, K 46,429
% Float 88.60%
Short Volume Ratio 0.41

Growth:

1-Year Return -72.71%
3-Year Return -88.79%
5-Year Return -87.45%
5-Year Revenue Growth -60.69%
5-Year Earnings Growth 66.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 03/17/25
Next Earnings Date 06/12/25
Earnings Per Share ttm -0.10
EPS Growth vs. Prev Qtr 60.00%
EPS Growth vs. Prev Year -162.69%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 0.100 on 11/15/24
Next Ex-Dividends Date 11/15/24
Dividend Payable Date 12/02/24
Dividend Payout Ratio 107.19%

ENZ Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -10.99%
Return-on-Assets % -7.48%
Profit Margin % -81.73%
Debt/Equity 0.00
Price/Sales 0.63
Price/Cash Flow N/A
Price/Book 0.35
Book Value/Share 0.89
Interest Coverage -48.10

ENZ Dividends

Date Value
11/15/24 $0.1000
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar